CAMP4 Therapeutics Receives Clearance From Australia’s TGA And Local HREC To Initiate Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic For SYNGAP1-Related Disorder
Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorderRegulatory milestone enables Company to raise up to $50 million through second closing of
CAMP4 Therapeutics got permission from Australia to test a new medicine designed to help people with a rare genetic disorder called SYNGAP1. When a company gets approval to start testing a new medicine on humans, it's a sign the idea passed important safety checks and the company is moving forward with its plan.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.